Larvol Delta - Bridge-Biotherapeutics-Enters-into-an-OptiontoLicense-Agreement-with-CellionBioMed-to-Develop-BBT301-for-the-Treatment-of-Multiple-Fibrotic-Diseases

BBT-301 - CellionBioMed, Bridge Biotherap

https://www.prnewswire.com/news-releases/bridge-biotherapeutics-enters-into-an-option-to-license-agreement-with-cellionbiomed-to-develop-bbt-301-for-the-treatment-of-multiple-fibrotic-diseases-301496470.html

Mar 7, 2022

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev